Literature DB >> 32193847

Evaluation and Recommendation of the 8th Edition of American Joint Committee on Cancer (AJCC) Staging System for Intrahepatic Cholangiocarcinoma (ICC) in 820 Patients from the Surveillance, Epidemiology, and End Results (SEER) Database.

Wu RuiYang1,2, Yang ZhiMing2, Feng Jiao2,3, Zhang Liang2, Zhang Gang4,5.   

Abstract

BACKGROUND: The AJCC made four changes to T category in the 8th AJCC stage for ICC, but this is a topic of debate.
METHODS: Data from 820 patients with ICC were extracted from the SEER database. Survival analysis of the 8th AJCC stage was examined.
RESULTS: To verify the four T staging changes by survival analysis: prognosis of patients with tumor size > 5 cm was poorer than that with tumor size ≤ 5 cm (P < 0.05); in N0M0 cohort, there was no significant difference in survival between solitary tumor with vascular invasion and multiple tumors (P = 0.092), tumor perforating the visceral peritoneum with and without involving local extrahepatic structures by direct invasion (P = 0.470), and tumor with and without periductal invasion (PI) (P = 0.220). The prognosis of patients with ≥ 4 positive lymph nodes was relatively poor compared with 1-3 positive lymph nodes (P = 0.037) and similar to patients with stage IV (8th AJCC, P = 0.585).
CONCLUSION: This study found that there was no significant difference in survival between tumor perforating the visceral peritoneum with and without involving local extrahepatic structures by direct invasion, whereas other T staging changes were effective. The inclusion of the number of positive lymph nodes in the 8th AJCC stage may improve prognostic discrimination in ICC patients.

Entities:  

Keywords:  8th edition AJCC stage; Intrahepatic cholangiocarcinoma; SEER

Mesh:

Year:  2020        PMID: 32193847     DOI: 10.1007/s11605-020-04557-y

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  1 in total

1.  [Intrahepatic cholangiocarcinoma: proposal of new macroscopic classification].

Authors:  J Yamamoto; T Kosuge; K Shimada; T Takayama; S Yamasaki; H Ozaki; M Makuuchi
Journal:  Nihon Geka Gakkai Zasshi       Date:  1993-11
  1 in total
  3 in total

1.  Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting-A Multi-Center Observational Study.

Authors:  Xiaoyan Ding; Guangxin Li; Wei Sun; Yanjun Shen; Ying Teng; Yawen Xu; Wendong Li; Mei Liu; Jinglong Chen
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

2.  Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System.

Authors:  Angela Lamarca; Alvaro Santos-Laso; Kirsten Utpatel; Adelaida La Casta; Simone Stock; Alejandro Forner; Jorge Adeva; Trine Folseraas; Luca Fabris; Rocio I R Macias; Marcin Krawczyk; Marek Krawczyk; Vincenzo Cardinale; Chiara Braconi; Domenico Alvaro; Matthias Evert; Jesus M Banales; Juan W Valle
Journal:  Hepatology       Date:  2021-06       Impact factor: 17.425

3.  Prognostic factors and survival outcome of primary pulmonary acinar cell carcinoma.

Authors:  Fan-Jie Meng; Zhao-Nan Sun; Zhi-Na Wang; Hong-Ming Ma; Wen-Cheng Zhang; Zhou-Yong Gao; Lin-Lin Ji; Fu-Kai Feng; Bo Yang; Chun-Yang Wang; Zi-Yi Chen; Nan Zhang; Guang-Shun Wang
Journal:  Thorac Cancer       Date:  2021-08-01       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.